Risk factors for intolerance of oral 5-aminosalicylic acid preparations in pediatric ulcerative colitis

Pediatr Int. 2023 Jan-Dec;65(1):e15553. doi: 10.1111/ped.15553.

Abstract

Background: No previous study of Japanese children with ulcerative colitis (UC) has reported the risk factors for intolerance of 5-aminosalicylic acid (5-ASA). We aimed to identify risk factors for intolerance of oral 5-ASA preparations in pediatric UC.

Methods: Patients with childhood-onset UC who were seen at our hospital between November 2003 and March 2020 were investigated. Intolerance of 5-ASA was defined as having clinical symptoms (pyrexia, abdominal pain, diarrhea, bloody stool) that worsened after starting oral administration of 5-ASA and improved after discontinuation of 5-ASA. Patient sex, age, body size, laboratory data, pediatric UC activity index scores, and colonoscopy-based determinations of the extent and severity of the affected lesion at initiation of 5-ASA of intolerant and tolerant groups were compared.

Results: Fifteen patients were in the intolerant group, and 37 were in the tolerant group. The leukocyte count, C-reactive protein level, and erythrocyte sedimentation rate were significantly higher in the intolerant group than the tolerant group; the albumin level in the intolerant group was significantly lower. All intolerant patients and 68% of tolerant patients had pancolitis (Paris classification E4). Patients with a large, affected area (Paris classifications E3 and E4) more frequently had intolerance to 5-ASA than patients with a small lesion. The cumulative Mayo endoscopic subscore (cMES), which is the sum of MES scores for six regions of the large intestine, was significantly higher in the intolerant group.

Conclusions: Pediatric UC patients with more intense inflammation and a large lesion could have an increased risk of intolerance for 5-ASA.

Keywords: 5-aminosalicylic acid, intolerance, pediatric, risk factor, ulcerative colitis.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Child
  • Colitis, Ulcerative* / drug therapy
  • Humans
  • Mesalamine* / adverse effects
  • Risk Factors

Substances

  • Mesalamine
  • Anti-Inflammatory Agents, Non-Steroidal

Supplementary concepts

  • Pediatric ulcerative colitis